Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer - Barker, A J; Gibson, K H; Grundy, W (Bioorg Med Chem Lett, 2001)
, et al.